Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

NCT07313384 | Recruiting

• 1 other identifier: 2371702-1
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 2

Brief Summary

The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.

Conditions

Obesity Type 2 Diabetes Mellitus; Obesity (Disorder)

Keywords

GLP-1 Therapy; Nutrition Support; Obesity; Weight loss therapy

Outcome Measures

Primary Outcomes (1)

• Change in Healthy Eating Index

  The Healthy Eating Index (HEI) is a scoring metric developed by the U.S. Department of Agriculture (USDA) and the NCI to assess how well a person's diet conforms to the Dietary Guidelines for Americans. It evaluates the consumption of 13 dietary components, including both adequacy (foods to increase) and moderation (foods to decrease). The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines.

  Baseline and 12-weeks

Secondary Outcomes (1)

• Change in Body Weight

  Baseline and 12 weeks

Study Arms (1)

GLP-1 Therapy

Individuals prescribed with GLP-1 Therapy for obesity or T2DM management.

Drug: GLP-1 Therapy

Interventions

GLP-1 Therapy DRUG

Exposure to GLP-1 Therapy for obesity or T2DM management.

GLP-1 Therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The recruitment will be conducted at the Prisma Health Weight Management Institute in Greenville, South Carolina, with support from the on-site research team. A total of 50 patients will be enrolled. Eligible individuals will be adults aged 18 years or older who have recently been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication.

You may qualify if:

• Adults aged 18 and older
• Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication
• Has regular access to a smartphone and internet to complete short surveys and food recalls online
• Willing to sign informed consent.

You may not qualify if:

• Already began the GLP-1 medication
• Have medical concerns making participation unsafe

Sponsors & Collaborators

• University of South Carolina: lead
• Prisma Health-Upstate: collaborator

Study Sites (2)

University South Carolina

Columbia, South Carolina, 20208, United States

ENROLLING BY INVITATION

Prisma Health Weight Management Institute

Greenville, South Carolina, 29607, United States

RECRUITING

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 12 Weeks
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Posdoctoral Fellow

Study Record Dates

• First Submitted: December 1, 2025
• First Posted: December 31, 2025
• Study Start: February 11, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: February 19, 2026

Record last verified: 2026-02

Locations

US (2)